New Patent Expands Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Suite to 20 Granted Worldwide (First in Japan)

• Drug delivery platform developer Lexaria Bioscience recently received its 20th patent — granted in Japan for beverages with lipophilic active agents
• The active agents include non-psychoactive cannabinoids and over-the-counter NSAIDS such as ibuprofen and aspirin that target pain and inflammation
• Lexaria’s DehydraTECH platform transforms drugs into a powder or liquid form that maintains the drug’s efficacy and allows it to be assimilated by the body more rapidly than normal oral ingestion of pills
• The company will also announce the latest results from six key R&D projects focusing on concentration levels, tolerability and avoidance of incidental new molecular entities (“NMEs”) soon

Drug assimilation technology innovator Lexaria Bioscience (NASDAQ: LEXX) is demonstrating the versatility of  its DehydraTECH platform with the announcement of a patent for “stable ready-to-drink beverage compositions comprising lipophilic active agents” — the company’s first granted in Japan.

“This new patent adds to our existing suite of granted patents spanning the EU, the U.S., India and Australia, and continues to build value for Lexaria shareholders and clients,” CEO Chris Bunka stated (https://cnw.fm/Cj8Sh). 

The DehydraTECH technology converts drugs into a powder or liquid form that will make them orally ingestible at a level of quick absorption and efficacy that is competitive with smoked or vaporized drug use but without the risk of lung harm that may be a consequence of inhaling drugs.

Processing drugs with DehydraTECH is being further evaluated through the company’s research and development program to establish that the drugs do not undergo unexpected changes in the process that would affect their safe use, and Lexaria expects to report its latest findings among six key R&D projects in the coming months (https://cnw.fm/LamDX). 

The patent for beverage compositions with lipophilic active agents in Japan references active ingredients such as non-psychoactive cannabinoids and NSAIDS (ibuprofen, aspirin and similar OTC anti-inflammatory pain relievers). 

According to the announcement, Lexaria has 13 patent families among its worldwide patent applications. The Japan patent is the third one granted in its third family, and the 20th patent overall. 

Earlier this month, Lexaria announced its voluntary delisting of its common shares from the Canadian Securities Exchange (CSE ticker LXX) in order to focus its resources on the applied R&D programs, reduce fees and managerial requirements that came with a dual listing and to provide more liquidity for shareholders.

“Since Lexaria’s shares began trading on the Nasdaq in January 2021, the overwhelming majority of trading has moved to Nasdaq,” the announcement states (https://cnw.fm/oUKL1).

In animal studies, DehydraTECH-delivered drugs have been shown to reach the bloodstream in minutes instead of hours, thanks to molecular delivery through the lymphatic system instead of the digestive system and its “first pass” liver exposure. 

DehydraTECH thereby eliminates concerns about unwanted tastes and odors accompanying the medicines and increases bio-absorption of the partner drugs into blood circulation by 100 to 500 percent with even greater bio-absorption measured in brain tissue, which establishes the potential for advancing treatment of central nervous system disorders. 

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About HempWire

HempWire (HW) is a dedicated information provider focused on (1) aggregating hemp-related news, (2) issuing HempNewsBreaks designed to update investors on the latest developments in the hemp market, (3) enhancing corporate news releases, (4) providing full-service distribution and social media offerings to public and private client-partners and (5) designing and implementing all-inclusive corporate communication solutions. HW is strategically positioned within the rapidly expanding hemp sector with a team of journalists working to help a growing roster of public and private companies reach a wide audience of investors, consumers and members of the media. We leverage a vast network of more than 5,000 key syndication outlets to deliver unparalleled visibility, recognition and content to the hemp industry. HempWire (HW) is where HEMP news, content and information converge.

To receive instant SMS alerts, text HEMPWIRE to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.hempwire.com

Please see full terms of use and disclaimers on the HempWire website applicable to all content provided by HW, wherever published or re-published: https://www.hempwire.com/Disclaimer

Do you have a questions or are you interested in working with HW? Ask our Editor

HempWire (HW)
Denver, Colorado
www.hempwire.com
303.498.7722 Office
Editor@HempWire.net

HempWire is part of the InvestorBrandNetwork.